REGENXBIO, Inc. RGNX

Investing.com -- Regenxbio Inc (NASDAQ:RGNX) shares rose 4.8% in premarket trading Friday after the company presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy at the Retina Society Annual Scientific Meeting.

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive long-term follow-up data from the Phase II ALTITUDE® study of investigational surabgenelomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal delivery. These new data were presented at the Retina Society 59th Annual Scientific Meeting in Los Angeles.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

Regenxbio Inc. (NASDAQ:RGNX) suffered another setback in its effort to bring RGX-121 to patients with Hunter syndrome. The FDA placed the experimental gene therapy on clinical hold after spinal scans identified abnormalities in five treated participants, and Reuters reported that Regenxbio shares fell more than 24% in premarket trading following the announcement. The findings add […]

REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.

Clear Street said the FDA decision would significantly delay Regenxbio’s resubmission of its application and a potential voucher that could bring in additional cash.

The update follows the detection of asymptomatic findings in the spine MRIs of five participants enrolled in the CAMPSIITE study.

BofA called the clinical hold on RGX-121 disappointing and a reversal of July’s progress but kept a $15 price target on the stock.

Healthcare stocks were decreasing Monday afternoon, with the NYSE Healthcare Index and the State Str

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company’s investigational therapy for Hunter syndome.

Regenxbio said the FDA has placed a clinical hold on its Hunter syndrome therapy after the discovery of unusual spine MRI findings in five participants in a study.

REGENXBIO Inc. (NASDAQ:RGNX) shares tumbled 35% after the U.

Investigators detected masses on the spines of five patients who received its Hunter syndrome treatment, leading to the program’s second clinical hold this year.

REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S. Food and Drug Administration (FDA) placed a clinical hold on RGX-121 following the discovery of asymptomatic spine MRI findings in five participants in the CAMPSIITE® study; REGENXBIO does not expect to resubmit the RGX-121 Biologics License Application (BLA) in the near